Evaluating the Association of Inflammatory Response to Intestinal Leakage in Patients Receiving Chemotherapy for Stage 3 Colon Cancer

Overview

Información sobre este estudio

To study intestinal permeability in participants with stage 3 colon cancer before and during chemotherapy and compare with controls with normal colon, chronic ulcerative colitis (CUC) and carcinoid syndrome

To study the correlation between intestinal permeability and symptoms severity during 5-FU chemotherapy

To study the correlation between intestinal permeability and neutrophils to lymphocytes ratio (NLR) before and during chemotherapy

To analyze the changes in expression levels of genes encoding intercellular junction proteins in all groups

To determine if diarrhea in participants with carcinoid syndrome is associated with increasedintestinal permeability

Elegibilidad para la participación

Los requisitos de elegibilidad de los participantes incluyen la edad, el sexo, el tipo y el estadio de la enfermedad, y los problemas de salud o tratamientos previos. Las pautas difieren de un estudio a otro e identifican quiénes pueden o no pueden participar. No hay garantía de que cada persona elegible que desee participar en un ensayo se inscribirá. Comunícate con el equipo del estudio para analizar la elegibilidad del estudio y la posible participación.

Inclusion Criteria

Age ≥18 years, male or female

For the Colon cancer subjects: Diagnosis of stage 3 colon cancer without IBD before treatment, during treatment with 5-FU based chemotherapy and post treatment.

Normal colon participants :  Normal colonoscopy without current adenomatous polyps, IBD, critical illness, obesity, celiac disease, NASH, IBS, food allergy, malnutrition or current history of diarrhea. 

Polyp participants; participants with advanced adenoma (> 1cm in size; villous histology and/or high grade dysplasia without IBD

Active Chronic ulcerative colitis:  participants with active CUC.

Carcinoid syndrome: participants with carcinoid syndrome.

Can swallow the mannitol capsule and drink up to 200 ml of water (or approximately 8 cups) and agrees to undergo urine testing up to 3 times during the study.

Exclusion Criteria

Participants with prior GI tract surgical (small or large bowel) resections

For normal colon participants: no h/o IBD critical illness, obesity, celiac disease, NASH, IBS, food allergy, malnutrition or current history of diarrhea.

Women who are pregnant or breast-feeding

Sedes participantes de Mayo Clinic

Los estatus de los estudios cambian con frecuencia. Comunícate con el equipo del estudio para obtener la información más actualizada acerca de la posibilidad de participar.

Sede de Mayo Clinic Estatus

Rochester, Minn.

Investigador principal de Mayo Clinic

Lisa Boardman, M.D.

Cerrado para la inscripción

More information

Publicaciones

Publications are currently not available
.
CLS-20306554

Mayo Clinic Footer